Lloyd M. Segal, MBA

In addition to his role as an advisor to Trepso, Lloyd is the President and CEO of Repare Therapeutics (Nasdaq:RPTX), a leading precision oncology company developing novel cancer therapeutics. Prior to Repare, Lloyd was a Managing Partner with Persistence Capital Partners, Canada’s leading healthcare private equity investor. Lloyd began his professional career as an associate with McKinsey & Company, and subsequently served as chief executive officer of several emerging biotechnology companies including Advanced Bioconcept Inc. (sold to Perkin-Elmer), Caprion Pharmaceuticals Inc. (now CellCarta Inc.), which he co-founded, and Thallion Pharmaceuticals Inc.

Lloyd has served on the boards of several public and private US and Canadian companies. He is currently a member of the Board of GBC American Fund, a US growth-focused mutual fund, and previously served as the Chairman of the Board for both LMC Diabetes & Endocrinology and MedReleaf (sold for $3.2b in 2018). He served as Entrepreneur-in-Residence with Versant Ventures from 2016 to 2020 and was honored in 2013 by the Financial Times as Outstanding Director of the Year for public companies. Lloyd holds a BA in politics from Brandeis University and an MBA from Harvard Business School.